Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 302 Parkinson Disease 4, Autosomal Dominant Lewy Body 180 Melanoma 166 Neoplasms 133 Squamous Cell Carcinoma of Head and Neck 126 Neoplasm Metastasis 98 Colorectal Neoplasms 96 Carcinoma, Renal Cell 80 Triple Negative Breast Neoplasms 75 Head and Neck Neoplasms 72 Stomach Neoplasms 70 Lung Neoplasms 68 Breast Neoplasms 60 Ovarian Neoplasms 56 Carcinoma, Transitional Cell 51 Uterine Cervical Neoplasms 44 Endometrial Neoplasms 44 Pancreatic Neoplasms 43 Urinary Bladder Neoplasms 40 Esophageal Neoplasms 40 Carcinoma, Hepatocellular 37 Small Cell Lung Carcinoma 30 Cholangiocarcinoma 24 Prostatic Neoplasms 22 Carcinoma 22 Lymphoma 20 Carcinoma, Squamous Cell 20 Recurrence 17 Sarcoma 16 Esophageal Squamous Cell Carcinoma 16

Interventions

Paclitaxel 3 liposomal doxorubicin 2 Carboplatin 2 1-dodecylpyridoxal 2 pembrolizumab 1 Gemcitabine 1 EP-100 membrane-disrupting peptide 1 Bevacizumab 1 AC 7700 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Recurrent × pembrolizumab × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡